• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Prime Medicine Inc.

    11/5/25 11:44:45 AM ET
    $PRME
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $PRME alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 4)


    PRIME MEDICINE INC

    (Name of Issuer)


    COMMON STOCK

    (Title of Class of Securities)


    74168J101

    (CUSIP Number)


    09/30/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    74168J101


    1Names of Reporting Persons

    FMR LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    6,724,867.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    6,731,796.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    6,731,796.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    3.8 %
    12Type of Reporting Person (See Instructions)

    HC


    SCHEDULE 13G

    CUSIP No.
    74168J101


    1Names of Reporting Persons

    Abigail P. Johnson
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    6,731,796.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    6,731,796.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    3.8 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    PRIME MEDICINE INC
    (b)Address of issuer's principal executive offices:

    60 FIRST ST.,Cambridge,MA,USA,02141
    Item 2. 
    (a)Name of person filing:

    FMR LLC
    (b)Address or principal business office or, if none, residence:

    245 Summer Street, Boston, Massachusetts 02210
    (c)Citizenship:

    Not applicable
    (d)Title of class of securities:

    COMMON STOCK
    (e)CUSIP No.:

    74168J101
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    6731796.00
    (b)Percent of class:

    3.8  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    Please see the responses to Items 5 and 6 on the cover page.

     (ii) Shared power to vote or to direct the vote:

    0.00

     (iii) Sole power to dispose or to direct the disposition of:

    6731796.00

     (iv) Shared power to dispose or to direct the disposition of:

    0.00

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Checkbox checked    Ownership of 5 percent or less of a class
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    One or more other persons are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the COMMON STOCK of PRIME MEDICINE INC. No one other person's interest in the COMMON STOCK of PRIME MEDICINE INC is more than five percent of the total outstanding COMMON STOCK.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.


    See attached Exhibit 99.
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    FMR LLC
     
    Signature:Stephanie J. Brown
    Name/Title:Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries*
    Date:11/04/2025
     
    Abigail P. Johnson
     
    Signature:Stephanie J. Brown
    Name/Title:Duly authorized under Power of Attorney effective as of January 26, 2023, by and on behalf of Abigail P. Johnson**
    Date:11/04/2025

    Comments accompanying signature:  * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. ** This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 31, 2023, accession number: 0000315066-23-000038.
    Exhibit Information

    Please see Exhibit 99 for 13d-1(k) (1) agreement.

    Get the next $PRME alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PRME

    DatePrice TargetRatingAnalyst
    5/27/2025$1.50Buy → Neutral
    Citigroup
    5/20/2025Overweight → Neutral
    Analyst
    5/20/2025Buy → Neutral
    H.C. Wainwright
    12/10/2024$10.00Mkt Outperform
    JMP Securities
    5/20/2024$10.00Buy
    H.C. Wainwright
    5/16/2024$10.00Neutral → Buy
    Citigroup
    4/22/2024$17.00Buy
    Chardan Capital Markets
    4/8/2024Buy
    TD Cowen
    More analyst ratings

    $PRME
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Prime Medicine downgraded by Citigroup with a new price target

    Citigroup downgraded Prime Medicine from Buy to Neutral and set a new price target of $1.50

    5/27/25 9:08:50 AM ET
    $PRME
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Prime Medicine downgraded by Analyst

    Analyst downgraded Prime Medicine from Overweight to Neutral

    5/20/25 8:09:46 AM ET
    $PRME
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Prime Medicine downgraded by H.C. Wainwright

    H.C. Wainwright downgraded Prime Medicine from Buy to Neutral

    5/20/25 8:09:36 AM ET
    $PRME
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $PRME
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Prime Medicine Appoints Matthew Hawryluk, Ph.D., M.B.A. as Chief Business Officer

    CAMBRIDGE, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (NASDAQ:PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced the appointment of Matthew Hawryluk, Ph.D., M.B.A. as Chief Business Officer (CBO). Dr. Hawryluk will lead Prime's corporate and business development initiatives, corporate strategy, and alliance management functions, advancing the company's efforts to expand the reach of Prime Editing through strategic partnerships and collaborations. "We are thrilled to welcome Matt to our leadership team," said Allan Reine, M.D., Chief Executive Officer of Prime Medicine. "Business devel

    11/3/25 8:01:00 AM ET
    $PRME
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Prime Medicine to Host Virtual KOL Event to Showcase Wilson's Disease Strategy

    CAMBRIDGE, Mass., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (NASDAQ:PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that it will host a virtual event on Wednesday, November 12, 2025, to discuss its liver disease franchise and strategy, with a focus on Wilson's Disease. Prime Medicine remains on track to file an investigational new drug (IND) and/or clinical trial application (CTA) for PM577, its Prime Editor for the treatment of H1069Q-driven Wilson's Disease, in the first half of 2026, with initial clinical data expected in 2027. Presentations will feature members of the Company's manag

    10/30/25 4:01:00 PM ET
    $PRME
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Prime Medicine to Participate in Upcoming Investor Conferences

    CAMBRIDGE, Mass., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (NASDAQ:PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that company management will participate in two upcoming conferences: H.C. Wainwright Genetic Medicines Virtual Conference 2025: Fireside chat will be available to view on demand beginning Tuesday, October 14, 2025. Company management will host virtual 1x1 meetings on Wednesday, October 15, 2025.Chardan's 9th Annual Genetic Medicines Conference: Allan Reine, M.D., will participate in a panel discussion, "Genome Editing: Next Wave Technologies," and host 1x1 meetings on Tues

    10/7/25 8:00:00 AM ET
    $PRME
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $PRME
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Technical Officer Lee Ann L.

    4 - Prime Medicine, Inc. (0001894562) (Issuer)

    8/5/25 8:44:42 PM ET
    $PRME
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Director Schenkein David P

    4 - Prime Medicine, Inc. (0001894562) (Issuer)

    8/5/25 8:43:37 PM ET
    $PRME
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Director Nelsen Robert

    4 - Prime Medicine, Inc. (0001894562) (Issuer)

    8/5/25 8:43:27 PM ET
    $PRME
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $PRME
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Prime Medicine Inc.

    SCHEDULE 13G/A - Prime Medicine, Inc. (0001894562) (Subject)

    11/5/25 11:44:45 AM ET
    $PRME
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Prime Medicine Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Prime Medicine, Inc. (0001894562) (Filer)

    9/8/25 8:04:35 AM ET
    $PRME
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 10-Q filed by Prime Medicine Inc.

    10-Q - Prime Medicine, Inc. (0001894562) (Filer)

    8/7/25 8:36:25 AM ET
    $PRME
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $PRME
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Gv 2021 Gp, L.L.C. bought $4,950,000 worth of shares (1,500,000 units at $3.30) (SEC Form 4)

    4 - Prime Medicine, Inc. (0001894562) (Issuer)

    8/5/25 4:07:52 PM ET
    $PRME
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Nelsen Robert bought $9,999,990 worth of shares (3,030,300 units at $3.30) (SEC Form 4)

    4 - Prime Medicine, Inc. (0001894562) (Issuer)

    8/1/25 7:19:58 PM ET
    $PRME
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Large owner Arch Venture Partners Xii, Llc bought $9,999,990 worth of shares (3,030,300 units at $3.30) (SEC Form 4)

    4 - Prime Medicine, Inc. (0001894562) (Issuer)

    8/1/25 7:19:33 PM ET
    $PRME
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $PRME
    Leadership Updates

    Live Leadership Updates

    View All

    Prime Medicine Appoints Matthew Hawryluk, Ph.D., M.B.A. as Chief Business Officer

    CAMBRIDGE, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (NASDAQ:PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced the appointment of Matthew Hawryluk, Ph.D., M.B.A. as Chief Business Officer (CBO). Dr. Hawryluk will lead Prime's corporate and business development initiatives, corporate strategy, and alliance management functions, advancing the company's efforts to expand the reach of Prime Editing through strategic partnerships and collaborations. "We are thrilled to welcome Matt to our leadership team," said Allan Reine, M.D., Chief Executive Officer of Prime Medicine. "Business devel

    11/3/25 8:01:00 AM ET
    $PRME
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Prime Medicine to Host Virtual KOL Event to Showcase Wilson's Disease Strategy

    CAMBRIDGE, Mass., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (NASDAQ:PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that it will host a virtual event on Wednesday, November 12, 2025, to discuss its liver disease franchise and strategy, with a focus on Wilson's Disease. Prime Medicine remains on track to file an investigational new drug (IND) and/or clinical trial application (CTA) for PM577, its Prime Editor for the treatment of H1069Q-driven Wilson's Disease, in the first half of 2026, with initial clinical data expected in 2027. Presentations will feature members of the Company's manag

    10/30/25 4:01:00 PM ET
    $PRME
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Prime Medicine Announces Strategic Restructuring to Focus on Opportunities in Large Genetic Liver Diseases, Cystic Fibrosis, and Partnered Programs Alongside CEO Leadership Transition

    -- Initial positive data from Phase 1/2 clinical trial of PM359 in CGD provide clinical proof-of-concept for Prime Editing as a transformative gene editing technology -- -- On-track to file IND and/or CTA for Wilson's Disease and AATD programs in 1H 2026 and mid-2026, respectively; initial clinical data for both expected in 2027 -- -- Allan Reine, M.D., CFO, to succeed Keith Gottesdiener, M.D., as CEO; Jeff Marrazzo, member of the Board of Directors, named Executive Chair -- -- Implementing cost cutting measures to significantly reduce cash needs in advance of key data inflection points -- CAMBRIDGE, Mass., May 19, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (NASDAQ:PRME), a biotech

    5/19/25 8:31:00 AM ET
    $PRME
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $PRME
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Prime Medicine Inc.

    SC 13D/A - Prime Medicine, Inc. (0001894562) (Subject)

    11/22/24 5:32:53 PM ET
    $PRME
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Prime Medicine Inc.

    SC 13G/A - Prime Medicine, Inc. (0001894562) (Subject)

    11/12/24 10:34:15 AM ET
    $PRME
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Prime Medicine Inc.

    SC 13G - Prime Medicine, Inc. (0001894562) (Subject)

    10/4/24 4:20:38 PM ET
    $PRME
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $PRME
    Financials

    Live finance-specific insights

    View All

    Prime Medicine Reports Third Quarter 2023 Financial Results and Provides Business Updates

    -- Presented new preclinical research across multiple programs, including proof-of-concept data from in vivo rodent and large animal studies, as well as updates on proprietary delivery systems -- -- Shared detailed safety evaluation of lead Prime Editors across multiple programs; preliminary off-target analyses did not identify off-target editing, supporting potential best-in-class safety profile -- -- Received U.S. FDA Rare Pediatric Drug designation for PM359 for CGD; initiated IND-enabling studies and remain on track to file IND application in 2024 -- -- Further extended intellectual property portfolio; U.S. PTO issued Prime Medicine's third patent, No. 11,795,452 --

    11/3/23 4:01:00 PM ET
    $PRME
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Prime Medicine Reports Second Quarter 2023 Financial Results and Provides Business Updates

    -- Presented new preclinical data demonstrating ability of Prime Editing to correct causative mutation of CGD and highlighting ability of PASSIGE™ platform to multiplex edit CAR-T cells at ASGCT Annual Meeting -- -- Entered strategic collaboration with Cimeio Therapeutics; multiplexing Cimeio's shielded variants with therapeutic edits may meaningfully expand reach of Prime Editing -- -- Cash, cash equivalents, investments and restricted cash balance of $221.1 million as of June 30, 2023 -- CAMBRIDGE, Mass., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (NASDAQ:PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapie

    8/7/23 4:01:00 PM ET
    $PRME
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care